SCHEMBL967439

SCHEMBL967439

COc1c(N2CC(C)N(C(=O)NC3CC3)C(C)C2)c(F)cc2c(=O)c(C(=O)NCc3ccc(Cl)cc3Cl)cn(C3CC3)c12

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.50
ALDH1A1 P00352 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HPGD P15428 4/20 0.48
KCNH2 Q12809 3/20 0.48
HSD17B10 Q99714 2/20 0.47
PRKD3 O94806 1/20 0.47
ALOX15 P16050 1/20 0.47
OPRM1 P35372 1/20 0.47
CLK2 P49760 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
CYP2C19 P33261 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12917502 1.00 KDM4E (0.50) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917506 0.93 KDM4E (0.51) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL13744621 0.92 KDM4E (0.52) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917479 0.92 KDM4E (0.49) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917505 0.92 KDM4E (0.49) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917507 0.92 KDM4E (0.52) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL5178558 0.91 KDM4E (0.46) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917470 0.91 KDM4E (0.49) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL966183 0.91 KDM4E (0.51) KDM4EALDH1A1TDP1LMNAPOLB
SCHEMBL12917471 0.90 KCNH2 (0.52) KDM4EALDH1A1TDP1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7867992-B2 such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses AICURIS GMBH & CO. KG (DE) 2011-01-11 US disclosed
US-20070293478-A1 Substituted quinolones BAYER HEALTHCARE AG (DE) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293478-A1 Substituted quinolones IRF3, TPMT, NQO2 KDM4E 1489/4885ALDH1A1 2853/4885TDP1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.